Document:

REGISTRATION
RIGHTS AGREEMENT

 

This
Registration Rights Agreement (the “Agreement”), dated as of
August 12, 2014 (the “Execution Date”), is entered into by and between Rich Pharmaceuticals, Inc., a Nevada
corporation (the “Company”), with its principal executive office at 995 Wilshire Blvd., Suite 900, Beverly
Hills, CA 90212, and Macallan Partners, a Delaware limited liability company (the “Investor”), with its principal
executive office at 245 Main Street, Suite 302, White Plains, New York 10601.

 

RECITALS:

 

Whereas,
pursuant to the Investment Agreement entered into by and between the Company and the Investor of this even date (the “Investment
Agreement”), the Company has agreed to issue and sell to the Investor an indeterminate number of shares of the Company’s
common stock, par value $0.0001 per share (the “Common Stock”), for an aggregate purchase price of up to Four
Million Dollars ($4,000,000); and

 

Whereas,
as an inducement to the Investors to execute and deliver the Investment Agreement, the Company has agreed to provide certain registration
rights under the Securities Act of 1933, as amended, and the rules and regulations thereunder, or any similar successor statute
(collectively, the “1933 Act”), and applicable state securities laws, with respect to the shares of Common
Stock issuable pursuant to the Investment Agreement.

Now therefore, in consideration of the foregoing promises and the mutual covenants
contained hereinafter and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
the Company and the Investor hereby agree as follows:

 

SECTION
I

DEFINITIONS

 

As
used in this Agreement, the following terms shall have the following meanings:

 

“Investor”
shall have the meaning set forth in the preamble.

 

“Effective
Date” shall mean the date the SEC declares effective under the 1933 Act the Registration Statement covering the Securities.

 

“Person”
means a corporation, a limited liability company, an association, a partnership, an organization, a business, an individual, a
governmental or political subdivision thereof or a governmental agency.

 

“Register,”
“Registered,” and “Registration” refer to the Registration effected by preparing and filing
one (1) or more Registration Statements in compliance with the 1933 Act and pursuant to Rule 415 under the 1933 Act or any successor
rule providing for offering securities on a continuous basis (“Rule 415”), and the declaration or ordering
of effectiveness of such Registration Statement(s) by the United States Securities and Exchange Commission (the “SEC”).

 

“Registrable
Securities” means (i) the shares of Common Stock issued or issuable pursuant to the Investment Agreement, and (ii) any
shares of capital stock issued or issuable with respect to such shares of Common Stock, if any, as a result of any stock split,
stock dividend, recapitalization, exchange or similar event or otherwise, which have not been (x) included in the Registration
Statement that has been declared effective by the SEC, or (y) sold under circumstances meeting all of the applicable conditions
of Rule 144 (or any similar provision then in force) under the 1933 Act.

 

“Registration
Statement” means the registration statement of the Company filed under the 1933 Act covering the Registrable Securities,
excluding any Form S-8 registration statement or amendment thereto.

 

“Rule
144” has the meaning set forth in Section 8.1.

 

“Financing
Agreements” shall mean this Agreement and the Investment Agreement between the Company and the Investor as of the date
hereof.

 

All
capitalized terms used in this Agreement and not otherwise defined herein shall have the same meaning ascribed to them as in the
Investment Agreement.

 

    	 

    	 

    

 

SECTION
II

REGISTRATION

 

2.1             
The Company shall use all commercially reasonable efforts to, within twenty-one (21) days of the date of this Agreement, file
with the SEC a Registration Statement or Registration Statements (as is necessary) on Form S-1 (or, if such form is unavailable
for such a registration, on such other form as is available for such registration), covering the resale the Registrable Securities,
which Registration Statement(s) shall state that, in accordance with Rule 416 promulgated under the 1933 Act, such Registration
Statement also covers such indeterminate number of additional shares of Common Stock as may become issuable upon stock splits,
stock dividends or similar transactions. The Registration Statement shall be prepared by Investor’s legal counsel and shall
be reviewed by Company’s legal counsel.

 

2.2             
The Company shall use all commercially reasonable efforts to have the initial Registration Statement, and each other Registration
Statement required to be filed pursuant to the terms hereof, declared effective by the SEC as soon as practicable, but in no event
later than ninety (90) days of the date of this Agreement (the “Effectiveness Deadline”).

 

2.3             
The Company agrees not to include any other securities in the Registration Statement covering the Registrable Securities without
Investor’s prior written consent which Investor may withhold in its sole discretion. Furthermore, the Company agrees that
it will not file any other Registration Statement for other securities, until thirty calendar days after the Registration Statement
for the Registrable Securities is declared effective by the SEC.

 

2.4             
Notwithstanding the registration obligations set forth in this Section 2.4, if the staff of the SEC (the “Staff”)
or the SEC informs the Company that all of the unregistered Registrable Securities cannot, as a result of the application of Rule
415, be registered for resale as a secondary offering on a single Registration Statement, the Company agrees to promptly (i) inform
each of the holders thereof and use its commercially reasonable efforts to file amendments to the Registration Statement as required
by the SEC and/or (ii) withdraw the Registration Statement and file a new Registration Statement (the “New Registration
Statement”), in either case covering the maximum number of Registrable Securities permitted to be registered by the
SEC, on Form S-1 to register for resale the Registrable Securities as a secondary offering. If the Company amends the Registration
Statement or files a New Registration Statement, as the case may be, under clauses (i) or (ii) above, the Company will use its
commercially reasonable efforts to file with the SEC, as promptly as allowed by the Staff or SEC, one or more registration statements
on Form S-1 to register for resale those Registrable Securities that were not registered for resale on the Registration Statement,
as amended, or the New Registration Statement. Additionally, the Company shall have the ability to file one or more New Registration
Statements to cover the Registrable Securities once the Shares under the initial Registration Statement referenced in Section
2.1 have been sold.

 

SECTIONIII

RELATED OBLIGATIONS

 

At
such time as the Company is obligated to prepare and file the Registration Statement with the SEC pursuant to Section 2, the Company
will affect the registration of the Registrable Securities in accordance with the intended method of disposition thereof and,
with respect thereto, the Company shall have the following obligations:

 

3.1             
The Company shall use all commercially reasonable efforts to cause such Registration Statement relating to the Registrable Securities
to become effective and shall keep such Registration Statement effective until the earlier to occur of the date on which (A) the
Investor shall have sold all the Registrable Securities; (B) the Investor has no right to acquire any additional shares of Common
Stock under the Investment Agreement; (C) have been sold pursuant to Rule 144 or may be sold without volume or manner-of-sale
restrictions pursuant to Rule 144; or (D) 48 months following the Effectiveness Date (the “Registration Period”).

 

3.2             
The Company shall prepare and file with the SEC such amendments (including post-effective amendments) and supplements to the Registration
Statement and the prospectus used in connection with such Registration Statement, which prospectus is to be filed pursuant to
Rule 424 promulgated under the 1933 Act, as may be necessary to keep such Registration Statement effective during the Registration
Period, and, during such period, comply with the provisions of the 1933 Act with respect to the disposition of all Registrable
Securities of the Company covered by such Registration Statement until such time as all of such Registrable Securities shall have
been disposed of in accordance with the intended methods of disposition by the Investor thereof as set forth in such Registration
Statement. In the event the number of shares of Common Stock covered by the Registration Statement filed pursuant to this Agreement
is at any time insufficient to cover all of the Registrable Securities, the Company shall amend such Registration Statement, or
file a new Registration Statement (on the short form available therefor, if applicable), or both, so as to cover all of the Registrable
Securities, in each case, as soon as practicable, but in any event within thirty (30) calendar days after the necessity therefor
arises (based on the then Purchase Price of the Common Stock and other relevant factors on which the Company reasonably elects
to rely), assuming the Company has sufficient authorized shares at that time, and if it does not, within thirty (30) calendar
days after such shares are authorized. The Company shall use commercially reasonable efforts to cause such amendment and/or new
Registration Statement to become effective as soon as practicable following the filing thereof.

 

3.3             
The Company shall make available to the Investor whose Registrable Securities are included in any Registration Statement and its
legal counsel without charge (i) promptly after the same is prepared and filed with the SEC at least one (1) copy of such Registration
Statement and any amendment(s) thereto, including financial statements and schedules, all documents incorporated therein by reference
and all exhibits, the prospectus included in such Registration Statement (including each preliminary prospectus) and, with regards
to such Registration Statement(s), any correspondence by or on behalf of the Company to the SEC or the staff of the SEC and any
correspondence from the SEC or the staff of the SEC to the Company or its representatives; (ii) upon the effectiveness of any
Registration Statement, the Company shall make available copies of the prospectus, via EDGAR, included in such Registration Statement
and all amendments and supplements thereto; and (iii) such other documents, including copies of any preliminary or final prospectus,
as the Investor may reasonably request from time to time to facilitate the disposition of the Registrable Securities.

 

    	2

    	 

    

 

3.4             
The Company shall use commercially reasonable efforts to (i) register and qualify the Registrable Securities covered by the Registration
Statement under such other securities or “blue sky” laws of such states in the United States as the Investor reasonably
requests; (ii) prepare and file in those jurisdictions, such amendments (including post-effective amendments) and supplements
to such registrations and qualifications as may be necessary to maintain the effectiveness thereof during the Registration Period;
(iii) take such other actions as may be necessary to maintain such registrations and qualifications in effect at all times during
the Registration Period, and (iv) take all other actions reasonably necessary or advisable to qualify the Registrable Securities
for sale in such jurisdictions; provided, however, that the Company shall not be required in connection therewith or as a condition
thereto to (x) qualify to do business in any jurisdiction where it would not otherwise be required to qualify but for this Section
3.4, or (y) subject itself to general taxation in any such jurisdiction. The Company shall promptly notify the Investor who holds
Registrable Securities of the receipt by the Company of any notification with respect to the suspension of the registration or
qualification of any of the Registrable Securities for sale under the securities or “blue sky” laws of any jurisdiction
in the United States or its receipt of actual notice of the initiation or threatening of any proceeding for such purpose.

 

3.5             
As promptly as practicable, but in no event more than three (3) calendar days, after becoming aware of such event, the Company
shall notify Investor in writing of the happening of any event as a result of which the prospectus included in the Registration
Statement, as then in effect, includes an untrue statement of a material fact or omission to state a material fact required to
be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading
(“Registration Default”) and use all diligent efforts to promptly prepare a supplement or amendment to such
Registration Statement and take any other necessary steps to cure the Registration Default (which, if such Registration Statement
is on Form S-3, may consist of a document to be filed by the Company with the SEC pursuant to Section 13(a), 13(c), 14 or 15(d)
of the 1934 Act (as defined below) and to be incorporated by reference in the prospectus) to correct such untrue statement or
omission, and make available copies of such supplement or amendment to the Investor. The Company shall also promptly notify the
Investor (i) when a prospectus or any prospectus supplement or post-effective amendment has been filed, and when the Registration
Statement or any post-effective amendment has become effective (the Company will prepare notification of such effectiveness which
shall be delivered to the Investor on the same day of such effectiveness and by overnight mail), additionally, the Company will
promptly provide to the Investor, a copy of the effectiveness order prepared by the SEC once it is received by the Company; (ii)
of any request by the SEC for amendments or supplements to the Registration Statement or related prospectus or related information,
(iii) of the Company’s reasonable determination that a post-effective amendment to the Registration Statement would be appropriate,
(iv) in the event the Registration Statement is no longer effective, or (v) if the Registration Statement is stale as a result
of the Company’s failure to timely file its financials or otherwise

 

3.6             
The Company shall use all commercially reasonable efforts to prevent the issuance of any stop order or other suspension of effectiveness
of the Registration Statement, or the suspension of the qualification of any of the Registrable Securities for sale in any jurisdiction
and, if such an order or suspension is issued, to obtain the withdrawal of such order or suspension at the earliest possible moment
and to notify the Investor holding Registrable Securities being sold of the issuance of such order and the resolution thereof
or its receipt of actual notice of the initiation or threat of any proceeding concerning the effectiveness of the registration
statement.

 

3.7             
The Company shall permit the Investor and one (1) legal counsel, designated by the Investor, to review and comment upon the Registration
Statement and all amendments and supplements thereto at least three (3) calendar day prior to their filing with the SEC, provided,
however, that the Company is under no obligation to make changes to the Registration Statement and all amendments or supplements
thereto based on comments from the Investor and its legal counsel. However, any postponement of a filing of a Registration Statement
or any postponement of a request for acceleration or any postponement of the effective date or effectiveness of a Registration
Statement by written request of the Investor (collectively, the “Investor’s Delay”) shall not act to
trigger any penalty of any kind, or any cash amount due or any in-kind amount due the Investor from the Company under any and
all agreements of any nature or kind between the Company and the Investor. The event(s) of an Investor’s Delay shall act
to suspend all obligations of the Company relating to having the Registration Statement filed and declared effective by the SEC
under the Financing Agreements between the Company and the Investor, including but not limited to Sections 2.2 and 2.3 of this
Agreement.

 

3.8             
Intentionally Omitted.

 

3.9             
The Company shall hold in confidence and not make any disclosure of information concerning the Investor unless (i) disclosure
of ssuch information is necessary to comply with federal or state securities laws, (ii) the disclosure of such information is
necessary to avoid or correct a misstatement or omission in any Registration Statement, (iii) the release of such information
is ordered pursuant to a subpoena or other final, non-appealable order from a court or governmental body of competent jurisdiction,
or (iv) such information has been made generally available to the public other than by disclosure in violation of this Agreement
or any other agreement. The Company agrees that it shall, to the extent permitted by law, upon learning that disclosure of such
information concerning the Investor is sought in or by a court or governmental body of competent jurisdiction or through other
means, give prompt written notice to the Investor and allow the Investor, at the Investor’s expense, to undertake appropriate
action to prevent disclosure of, or to obtain a protective order covering such information.

 

3.10         
The Company shall use all commercially reasonable efforts to maintain designation and quotation of all the Registrable Securities
covered by any Registration Statement on the Principal Market. If, despite the Company’s commercially reasonable efforts,
the Company is unsuccessful in satisfying the preceding sentence, it shall use commercially reasonable efforts to cause all the
Registrable Securities covered by any Registration Statement to be listed on each other national securities exchange and automated
quotation system, if any, on which securities of the same class or series issued by the Company are then listed, if any, if the
listing of such Registrable Securities is then permitted under the rules of such exchange or system. The Company shall pay all
fees and expenses in connection with satisfying its obligation under this Section 3.10.

 

3.11         
The Company shall cooperate with the Investor to facilitate the prompt preparation and delivery of certificates representing the
Registrable Securities to be offered pursuant to the Registration Statement and enable such certificates to be in such denominations
or amounts, as the case may be, as the Investor may reasonably request (and after any sales of such Registrable Securities by
the Investor, such certificates not bearing any restrictive legend).

 

3.12         
The Company shall provide a transfer agent for all the Registrable Securities not later than the effective date of the first Registration
Statement filed pursuant hereto.

 

    	3

    	 

    

 

3.13         
If requested by the Investor, the Company shall (i) as soon as reasonably practical incorporate in a prospectus supplement or
post-effective amendment such information as the Investor reasonably determines should be included therein relating to the sale
and distribution of Registrable Securities, including, without limitation, information with respect to the offering of the Registrable
Securities to be sold in such offering; (ii) make all required filings of such prospectus supplement or post-effective amendment
as soon as reasonably possible after being notified of the matters to be incorporated in such prospectus supplement or post-effective
amendment; and (iii) supplement or make amendments to any Registration Statement if reasonably requested by the Investor.

 

3.14         
The Company shall use all commercially reasonable efforts to cause the Registrable Securities covered by the applicable Registration
Statement to be registered with or approved by such other governmental agencies or authorities as may be necessary to facilitate
the disposition of such Registrable Securities.

 

3.15         
The Company shall otherwise use all commercially reasonable efforts to comply with all applicable rules and regulations of the
SEC in connection with any registration hereunder.

 

3.16         
Within three (3) business day after the Registration Statement which includes theRegistrable Securities is declared effective
by the SEC, the Company shall deliver to the transfer agent for such Registrable Securities, with copies to the Investor, confirmation
that such Registration Statement has been declared effective by the SEC in the form attached hereto as Exhibit A.

 

3.17         
The Company shall take all other reasonable actions necessary to expedite and facilitate disposition by the Investor of Registrable
Securities pursuant to the Registration Statement.

 

SECTION
IV

OBLIGATIONS OF THE INVESTOR

4.1             
At least five (5) calendar days prior to the first anticipated filing date of the Registration Statement the Company shall notify
the Investor in writing of the information the Company requires from the Investor for the Registration Statement. It shall be
a condition precedent to the obligations of the Company to complete the registration pursuant to this Agreement with respect to
the Registrable Securities and the Investor agrees to furnish to the Company that information regarding itself, the Registrable
Securities and the intended method of disposition of the Registrable Securities as shall reasonably be required to effect the
registration of such Registrable Securities and the Investor shall execute such documents in connection with such registration
as the Company may reasonably request. The Investor covenants and agrees that, in connection with any sale of Registrable Securities
by it pursuant to the Registration Statement, it shall comply with the “Plan of Distribution” section of the then
current prospectus relating to such Registration Statement.

 

4.2             
The Investor, by its acceptance of the Registrable Securities, agrees to cooperate with the Company as reasonably requested by
the Company in connection with the preparation and filing of any Registration Statement hereunder, unless the Investor has notified
the Company in writing of an election to exclude all of the Investor’s Registrable Securities from such Registration Statement.

 

4.3             
The Investor agrees that, upon receipt of written notice from the Company of the happening of any event of the kind described
in Section 3.6 or the first sentence of 3.5, the Investor will immediately discontinue disposition of Registrable Securities pursuant
to any Registration Statement(s) covering such Registrable Securities until the Investor’s receipt of the copies of the
supplemented or amended prospectus contemplated by Section 3.6 or the first sentence of 3.5.

 

SECTION
V

EXPENSES OF REGISTRATION

 

All
legal expenses, other than underwriting discounts and commissions and other than as set forth in the Investment Agreement, incurred
in connection with registrations including comments, filings or qualifications pursuant to Sections 2 and 3, including, without
limitation, all registration, listing and qualifications fees, printing fees, and the legal fees of Investor’s counsel of
$20,000, shall be paid by the Company from the first Drawdown.

 

    	4

    	 

    

  

SECTION
VI

INDEMNIFICATION

 

In
the event any Registrable Securities are included in the Registration Statement under this Agreement:

 

6.1             
To the fullest extent permitted by law, the Company, under this Agreement, will, and hereby does, indemnify, hold harmless and
defend the Investor who holds Registrable Securities, the directors, officers, partners, employees, counsel, agents, representatives
of, and each Person, if any, who controls, any Investor within the meaning of the 1933 Act or the Securities Exchange Act of 1934,
as amended (the “1934 Act”) (each, an “Indemnified Person”), against any losses, claims,
damages, liabilities, judgments, fines, penalties, charges, costs, attorneys’ fees, amounts paid in settlement or expenses,
joint or several (collectively, “Claims”), incurred in investigating, preparing or defending any action, claim,
suit, inquiry, proceeding, investigation or appeal taken from the foregoing by or before any court or governmental, administrative
or other regulatory agency, body or the SEC, whether pending or threatened, whether or not an indemnified party is or may be a
party thereto (“Indemnified Damages”), to which any of them may become subject insofar as such Claims (or actions
or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon: (i) any untrue statement
or alleged untrue statement of a material fact in the Registration Statement or any post-effective amendment thereto or in any
filing made in connection with the qualification of the offering under the securities or other “blue sky” laws of
any jurisdiction in which the Investor has requested in writing that the Company register or qualify the Registrable Securities,
or the omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which the statements therein were made, not misleading, (ii) any untrue statement
or alleged untrue statement of a material fact contained in the final prospectus (as amended or supplemented, if the Company files
any amendment thereof or supplement thereto with the SEC) or the omission or alleged omission to state therein any material fact
necessary to make the statements made therein, in light of the circumstances under which the statements therein were made, not
misleading, or (iii) any violation or alleged violation by the Company of the 1933 Act, the 1934 Act, any other state or federal
securities law, or any rule or regulation thereunder relating to the offer or sale of the Registrable Securities pursuant to the
Registration Statement (the matters in the foregoing clauses (i) through (iii) being, collectively, “Violations”).
Subject to the restrictions set forth in Section 6.3 the Company shall reimburse the Investor and each such controlling person,
promptly as such expenses are incurred and are due and payable, for any reasonable legal fees or other reasonable expenses incurred
by them in connection with investigating or defending any such Claim. Notwithstanding anything to the contrary contained herein,
the indemnification agreement contained in this Section 6.1: (i) shall not apply to a Claim arising out of or based upon a Violation
which is due to the inclusion in the Registration Statement of the information furnished to the Company by any Indemnified Person
expressly for use in connection with the preparation of the Registration Statement or any such amendment thereof or supplement
thereto; (ii) shall not be available to the extent such Claim is based on (a) a failure of the Investor to deliver or to cause
to be delivered the prospectus made available by the Company or (b) the Indemnified Person’s use of an incorrect prospectus
despite being promptly advised in advance by the Company in writing not to use such incorrect prospectus; (iii) any claims based
on the manner of sale of the Registrable Securities by the Investor or of the Investor’s failure to register as a dealer
under applicable securities laws; (iv) any omission of the Investor to notify the Company of any material fact that required disclosure
in the Registration Statement or prospectus relating to the Investor or the manner of sale; and (v) any amounts paid in settlement
of any Claim if such settlement is effected without the prior written consent of the Company, which consent shall not be unreasonably
withheld. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Indemnified
Person and shall survive the resale of the Registrable Securities by the Investor pursuant to the Registration Statement.

 

6.2             
In connection with any Registration Statement in which Investor is participating, the Investor agrees to severally and jointly
indemnify, hold harmless and defend, to the same extent and in the same manner as is set forth in Section 6.1, the Company, each
of its directors, each of its officers who signs the Registration Statement, each Person, if any, who controls the Company within
the meaning of the 1933 Act or the 1934 Act and the Company’s agents (collectively and together with an Indemnified Person,
an “Indemnified Party”), against any Claim or Indemnified Damages to which any of them may become subject,
under the 1933 Act, the 1934 Act or otherwise, insofar as such Claim or Indemnified Damages arise out of or are based upon any
Violation, in each case to the extent, and only to the extent, that such Violation is due to the inclusion in the Registration
Statement of willfully misleading written information furnished to the Company by the Investor expressly for use in connection
with such Registration Statement; and, subject to Section 6.3, the Investor will reimburse any legal or other expenses reasonably
incurred by them in connection with investigating or defending any such Claim; provided, however, that the indemnity agreement
contained in this Section 6.2 and the agreement with respect to contribution contained in Section 7 shall not apply to amounts
paid in settlement of any Claim if such settlement is effected without the prior written consent of the Investor, which consent
shall not be unreasonably withheld; provided, further, however, that the Investor shall only be liable under this Section 6.2
for that amount of a Claim or Indemnified Damages as does not exceed the net proceeds to such Investor as a result of the sale
of Registrable Securities pursuant to such Registration Statement. Such indemnity shall remain in full force and effect regardless
of any investigation made by or on behalf of such Indemnified Party and shall survive the resale of the Registrable Securities
by the Investor pursuant to the Registration Statement. Notwithstanding anything to the contrary contained herein, the indemnification
agreement contained in this Section 6.2 with respect to any preliminary prospectus shall not inure to the benefit of any Indemnified
Party if the untrue statement or omission of material fact contained in the preliminary prospectus were corrected on a timely
basis in the prospectus, as then amended or supplemented. This indemnification provision shall apply separately to each Investor
and liability hereunder shall not be joint and several.

 

6.3             
Promptly after receipt by an Indemnified Person or Indemnified Party under this Section6 of notice of the commencement of any
action or proceeding (including any governmental action or proceeding) involving a Claim, such Indemnified Person or Indemnified
Party shall, if a Claim in respect thereof is to be made against any indemnifying party under this Section 6, deliver to the indemnifying
party a written notice of the commencement thereof, and the indemnifying party shall have the right to participate in, and, to
the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume control of
the defense thereof with counsel mutually satisfactory to the indemnifying party and the Indemnified Person or the Indemnified
Party, as the case may be; provided, however, that an Indemnified Person or Indemnified Party shall have the right to retain its
own counsel with the fees and expenses to be paid by the indemnifying party, if, in the reasonable opinion of counsel retained
by the Indemnified Person or Indemnified Party, the representation by counsel of the Indemnified Person or Indemnified Party and
the indemnifying party would be inappropriate due to actual or potential differing interests between such Indemnified Person or
Indemnified Party and any other party represented by such counsel in such proceeding. The indemnifying party shall pay for only
one (1) separate legal counsel for the Indemnified Persons or the Indemnified Parties, as applicable, and such counsel shall be
selected by the Investor, if the Investor is entitled to indemnification hereunder, or the Company, if the Company is entitled
to indemnification hereunder, as applicable. The Indemnified Party or Indemnified Person shall cooperate fully with the indemnifying
party in connection with any negotiation or defense of any such action or Claim by the indemnifying party and shall furnish to
the indemnifying party all information reasonably available to the Indemnified Party or Indemnified Person which relates to such
action or Claim. The indemnifying party shall keep the Indemnified Party or Indemnified Person fully apprised at all times as
to the status of the defense or any settlement negotiations with respect thereto. No indemnifying party shall be liable for any
settlement of any action, claim or proceeding affected without its written consent, provided, however, that the indemnifying party
shall not unreasonably withhold, delay or condition its consent. No indemnifying party shall, without the consent of the Indemnified
Party or Indemnified Person, consent to entry of any judgment or enter into any settlement or other compromise which does not
include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party or Indemnified Person
of a release from all liability in respect to such Claim. Following indemnification as provided for hereunder, the indemnifying
party shall be subrogated to all rights of the Indemnified Party or Indemnified Person with respect to all third parties, firms
or corporations relating to the matter for which indemnification has been made. The failure to deliver written notice to the indemnifying
party within a reasonable time of the commencement of any such action shall not relieve such indemnifying party of any liability
to the Indemnified Person or Indemnified Party under this Section 6, except to the extent that the indemnifying party is prejudiced
in its ability to defend such action.

 

    	5

    	 

    

 

6.4             
The indemnity agreements contained herein shall be in addition to (i) any cause of action or similar right of the Indemnified
Party or Indemnified Person against the indemnifying party or others, and (ii) any liabilities the indemnifying party may be subject
to pursuant to the law.

 

SECTIONVII

CONTRIBUTION

 

7.1             
To the extent any indemnification by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make
the maximum contribution with respect to any amounts for which it would otherwise be liable under Section 6 to the fullest extent
permitted by law; provided, however, that: (i) no contribution shall be made under circumstances where the maker would not have
been liable for indemnification under the fault standards set forth in Section 6; (ii) no seller of Registrable Securities guilty
of fraudulent misrepresentation (within the meaning of Section 11(f) of the 1933 Act) shall be entitled to contribution from any
seller of Registrable Securities who was not guilty of fraudulent misrepresentation or the Company; and (iii) contribution by
any seller of Registrable Securities shall be limited in amount to the net amount of proceeds received by such seller from the
sale of such Registrable Securities.

 

SECTION
VIII

REPORTS
UNDER THE 1934 ACT

 

8.1             
With a view to making available to the Investor the benefits of Rule 144 promulgated under the 1933 Act or any other similar rule
or regulation of the SEC that may at any time permit the Investor to sell securities of the Company to the public without registration
(“Rule 144”), provided that the Investor holds any Registrable Securities are eligible for resale under Rule
144, the Company agrees to:

 

		a.	make
                                         and keep adequate public information available, as those terms are understood and defined
                                         in Rule 144;

 

		b.	file
                                         with the SEC in a timely manner all reports and other documents required of the Company
                                         under the 1933 Act and the 1934 Act so long as the Company remains subject to such requirements
                                         (it being understood that nothing herein shall limit the Company’s obligations
                                         under Section 5(c) of the Investment Agreement) and the filing of such reports and other
                                         documents is required for the applicable provisions of Rule 144; and

 

		c.	furnish
                                         to the Investor, promptly upon request, (i) a written statement by the Company that it
                                         has complied with the reporting requirements of Rule 144, the 1933 Act and the 1934 Act,
                                         (ii) a copy of the most recent annual or quarterly report of the Company and such other
                                         reports and documents so filed by the Company, and (iii) such other information as may
                                         be reasonably requested to permit the Investor to sell such securities pursuant to Rule
                                         144 without registration.

 

SECTION
X

MISCELLANEOUS

 

9.1             
NOTICES. Any notices or other communications required or permitted to be given under the terms of this Agreement that must
be in writing will be deemed to have been delivered (i) upon receipt, when delivered personally; (ii) upon receipt, when sent
by facsimile (provided a confirmation of transmission is mechanically or electronically generated and kept on file by the sending
party); or (iii) one (1) day after deposit with a nationally recognized overnight delivery service, in each case properly addressed
to the party to receive the same. The addresses and facsimile numbers for such communications shall be:

 

	If
                                         to the Company:

         

         

         

         
	Rich
                                         Pharmaceuticals, Inc.

        9595
        Wilshire Blvd., Suite 900

        Beverly
        Hills, CA 90212

        Attn:
        Ben Chang

        Facsimile:
        [fax number]

	 

        With
        a copy to:
	 

        name

        [address]

        Attn:
        name

        Facsimile:

         

	If
    to the Investor:	Macallan
                                         Partners, LLC

        245
        Main Street, Suite 302

        White
        Plains, New York 10601

        Attn:
        Rick Stilitino

        Facsimile:
        212-xxx-xxxx

	 	 
	With
    a copy to:	Szaferman
                                         Lakind Blumstein & Blader, PC

        101
        Grovers Mill Road, Suite 200

        Lawrenceville,
        NJ 08648

        Attn:
        Gregg E. Jaclin, Esq.

        Facsimile:
        609-557-0969

 

    	6

    	 

    

 

Each
party shall provide five (5) business days prior notice to the other party of any change in address, phone number or facsimile
number.

 

9.2             
NO WAIVERS. Failure of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party
in exercising such right or remedy, shall not operate as a waiver thereof.

 

 

9.3             
NO ASSIGNMENTS. The rights and obligations under this Agreement shall not be assignable.

 

9.4             
ENTIRE AGREEMENT/AMENDMENT. The Financing Agreements constitute the entire agreement among the parties hereto with respect
to the subject matter hereof and thereof. There are no restrictions, promises, warranties or undertakings, other than those set
forth or referred to herein and therein. This Agreement and the Financing Agreements supersede all prior agreements and understandings
among the parties hereto with respect to the subject matter hereof and thereof. The provisions of this Agreement may be amended
only with the written consent of the Company and Investor.

 

9.5             
HEADINGS. The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect
the meaning hereof. Whenever required by the context of this Agreement, the singular shall include the plural and masculine shall
include the feminine. This Agreement shall not be construed as if it had been prepared by one of the parties, but rather as if
all the parties had prepared the same.

 

9.6             
COUNTERPARTS. This Agreement may be executed in any number of counterparts and by the different signatories hereto on separate
counterparts, each of which, when so executed, shall be deemed an original, but all such counterparts shall constitute but one
and the same instrument. This Agreement may be executed by facsimile transmission, PDF, electronic signature or other similar
electronic means with the same force and effect as if such signature page were an original thereof.

 

9.7             
FURTHER ASSURANCES. Each party shall do and perform, or cause to be done and performed, all such further acts and things,
and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably
request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions
contemplated hereby.

 

9.8             
SEVERABILITY. In case any provision of this Agreement is held by a court of competent jurisdiction to be excessive in scope
or otherwise invalid or unenforceable, such provision shall be adjusted rather than voided, if possible, so that it is enforceable
to the maximum extent possible, and the validity and enforceability of the remaining provisions of this Agreement will not in
any way be affected or impaired thereby.

 

9.9             
Law Governing this Agreement. This Agreement shall be governed by and construed
in accordance with the laws of the State of New York without regard to principles of conflicts of laws. Any action brought by
either party against the other concerning the transactions contemplated by this Agreement shall be brought only in the state courts
of New York or in the federal courts located in the state and county of New York. The parties to this Agreement hereby irrevocably
waive any objection to jurisdiction and venue of any action instituted hereunder and shall not assert any defense based on lack
of jurisdiction or venue or based upon forum non conveniens. The parties executing this Agreement and other agreements
referred to herein or delivered in connection herewith on behalf of the Company agree to submit to the in personam jurisdiction
of such courts and hereby irrevocably waive trial by jury. The prevailing party shall be entitled to recover from the other
party its reasonable attorney’s fees and costs. In the event that any provision of this Agreement or any other agreement
delivered in connection herewith is invalid or unenforceable under any applicable statute or rule of law, then such provision
shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute
or rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect the validity or enforceability
of any other provision of any agreement. Each party hereby irrevocably waives personal service of process and consents to process
being served in any suit, action or proceeding in connection with this Agreement or any other Financing Agreements by mailing
a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address
in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of
process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other
manner permitted by law.

 

9.10         
NO THIRD PARTY BENEFICIARIES. This Agreement is intended for the benefit of the parties hereto and is not for the benefit
of, nor may any provision hereof be enforced by, any other person, except that the Company acknowledges that the rights of the
Investor may be enforced by its general partner. 

[Signature
page follows]

 

    	7

    	 

    

 

Your
signature on this signature page evidences your agreement to be bound by the terms and conditions of this Agreement as of the
date first written above. The undersigned signatory hereby certifies that he has read and understands this Agreement, and the
representations made by the undersigned in this Agreement are true and accurate, and agrees to be bound by its terms.

 

MACALLAN
PARTNERS, LLC

 

 

By:
/s/ Authorized Signatory

Name:

Title:

 

 

RICH
PHARMACEUTICALS, INC.

 

 

By:
/s/ Ben Chang

Name:
Ben Chang

Title:
Chief Executive Officer

 

 

 

 

[SIGNATURE
PAGE OF REGISTRATION RIGHTS AGREEMENT]

 

    	8

    	 

    

 

EXHIBIT
A

FORM
OF NOTICE OF EFFECTIVENESS

OF REGISTRATION STATEMENT

Date:
__________

[TRANSFER
AGENT]

Re:
Rich Pharmaceuticals, Inc.

Ladies
and Gentlemen:

We
are counsel to Rich Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and have represented the Company
in connection with that certain Investment Agreement (the “Investment Agreement”) entered into by and among the Company
and Macallan Partners, LLC (the “Investor”) pursuant to which the Company has agreed to issue to the Investor shares
of the Company’s common stock, $0.001 par value per share (the “Common Stock”) on the terms and conditions set
forth in the Investment Agreement. Pursuant to the Investment Agreement, the Company also has entered into a Registration Rights
Agreement with the Investor (the “Registration Rights Agreement”) pursuant to which the Company agreed, among other
things, to register the Registrable Securities (as defined in the Registration Rights Agreement), including the shares of Common
Stock issued or issuable under the Investment Agreement under the Securities Act of 1933, as amended (the “1933 Act”).
In connection with the Company’s obligations under the Registration Rights Agreement, on ___________ ___, 2014, the Company
filed a Registration Statement on Form S-1 (File No. 333-________) (the “Registration Statement”) with the Securities
and Exchange Commission (the “SEC”) relating to the Registrable Securities which names the Investor as a selling stockholder
thereunder.

In
connection with the foregoing, we advise you that a member of the SEC's staff has advised us by telephone that the SEC has entered
an order declaring the Registration Statement effective under the 1933 Act at ______ on __________, 20__ and we have no knowledge,
after telephonic inquiry of a member of the SEC's staff, that any stop order suspending its effectiveness has been issued or that
any proceedings for that purpose are pending before, or threatened by, the SEC and the Registrable Securities are available for
sale under the 1933 Act pursuant to the Registration Statement

 

 

Very
truly yours,

 

[Company
Counsel]

    	9RCHA	$350,000 CONVERTIBLE NOTE	
        Interest free if paid in full

        within 3 months

 

FOR VALUE RECEIVED, Rich Pharmaceuticals, Inc.,
a Nevada corporation (the "Issuer" of this Security) with at least 420,463,772 common shares issued and outstanding,
issues this Security and promises to pay to JMJ Financial, a Nevada sole proprietorship, or its Assignees (the "Investor")
the Principal Sum along with the Interest Rate and any other fees according to the terms herein. This Note will become effective
only upon execution by both parties and delivery of the first payment of Consideration by the Investor (the "Effective Date").

 

The Principal Sum is $350,000 (three hundred
fifty thousand) plus accrued and unpaid interest and any other fees. The Consideration is $315,000 (three hundred fifteen thousand)
payable by wire (there exists a $35,000 original issue discount (the "OID")). The Investor shall pay $55,000 of Consideration
upon closing of this Note. The Investor may pay additional Consideration to the Issuer in such amounts and at such dates as the
Investor may choose in its sole discretion. THE PRINCIPAL SUM DUE TO THE INVESTOR SHALL BE PRORATED BASED ON THE CONSIDERATION
ACTUALLY PAID BY INVESTOR (PLUS AN APPROXIMATE 10% ORIGINAL ISSUE DISCOUNT THAT IS PRORATED BASED ON THE CONSIDERATION ACTUALLY
PAID BY THE INVESTOR AS WELL AS ANY OTHER INTEREST OR FEES) SUCH THAT THE ISSUER IS ONLY REQUIRED TO REPAY THE AMOUNT FUNDED AND
THE ISSUER IS NOT REQUIRED TO REPAY ANY UNFUNDED PORTION OF THIS NOTE. The Maturity Date is two years from the Effective Date of
each payment (the "Maturity Date") and is the date upon which the Principal Sum of this Note, as well as any unpaid interest
and other fees, shall be due and payable. The Conversion Price is 60% of the lowest trade price in the 20 trading days previous
to the conversion (In the case that conversion shares are not deliverable by DWAC an additional 10% discount will apply; and if
the shares are ineligible for deposit into the OTC system and only eligible for Xclearing deposit an additional 5% discount shall
apply; in the case of both an additional cumulative 15% discount shall apply). Unless otherwise agreed in writing by both parties,
at no time will the Investor convert any amount of the Note into common stock that would result in the Investor owning more than
4.99% of the common stock outstanding.

 

1.                  
ZERO Percent Interest for the First Three Months. The Issuer may repay this Note at
any time on or before 90 days from the Effective Date, after which the Issuer may not make further payments on this Note prior
to the Maturity Date without written approval from the lnvestor. If the Issuer repays a payment of Consideration on or before 90
days from the Effective Date of that payment, the Interest Rate on that payment of Consideration shall be ZERO PERCENT (0%). If
the Issuer does not repay a payment of Consideration on or before 90 days from its Effective Date, a one-time Interest charge of
12% shall be applied to the Principal Sum. Any interest payable is in addition to the OID, and that OID (or prorated OID, if applicable)
remains payable regardless of time and manner of payment by the Issuer.

 

2.                  
Conversion. The Investor has the right, at any time after the Effective Date, at its
election, to convert all or part of the outstanding and unpaid Principal Sum and accrued interest (and any other fees) into shares
of fully paid and non-assessable shares of common stock of the Issuer as per this conversion formula: Number of shares receivable
upon conversion equals the dollar conversion amount divided by the Conversion Price. Conversions may be delivered to the Issuer
by method of the Investor's choice (including but not limited to email, facsimile, mail, overnight courier, or personal delivery),
and all conversions shall be cashless and not require further payment from the Investor. If no objection is delivered from the
Issuer to the Investor regarding any variable or calculation of the conversion notice within 24 hours of delivery of the conversion
notice, the Issuer shall have been thereafter deemed to have irrevocably confirmed and irrevocably ratified such notice of conversion
and waived any objection thereto. The Issuer shall deliver the shares from any conversion to the Investor (in any name directed
by the Investor) within 3 (three) business days of conversion notice delivery.

    	 

    	 

    

 

3.                  
Conversion Delays. If the Issuer fails to deliver shares in accordance with the timeframe
stated in Section 2, the Investor, at any time prior to selling all of those shares, may rescind any portion, in whole or in part,
of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal
Sum with the rescinded conversion shares returned to the Issuer (under the Investor's and the Issuer's expectations that any returned
conversion amounts will tack back to the original date of the Note). In addition, for each conversion, in the event that shares
are not delivered by the fourth business day (inclusive of the day of conversion), a penalty of $2,000 per day will be assessed
for each day after the third business day (inclusive of the day of the conversion) until share delivery is made; and such penalty
will be added to the Principal Sum of the Note (under the Investor's and the Issuer's expectations that any penalty amounts will
tack back to the original date of the Note).

 

4.                  
Reservation of Shares. At all times during which this Note is convertible, the Issuer
will reserve from its authorized and unissued Common Stock to provide for the issuance of Common Stock upon the full conversion
of this Note. The Issuer will at all times reserve at least 60,000,000 shares of Common Stock for conversion.

 

5.                  
This Section 5 intentionally left blank.

 

6.                  
This Section 6 intentionally left blank.

 

7.                  
Default. The following are events of default under this Note: (i) the Issuer shall
fail to pay any principal under the Note when du e and payable (or payable by conversion) thereunder; or (ii) the Issuer shall
fail to pay any interest or any other amount under the Note when due and payable (or payable by conversion) thereunder; or (iii)
a receiver, trustee or other similar official shall be appointed over the Issuer or a material part of its assets and such appointment
shall remain uncontested for twenty (20) days or shall not be dismissed or discharged within sixty (60) days; or (iv) the Issuer
shall become insolvent or generally fails to pay, or admits in writing its inability to pay, its debts as they become due, subject
to applicable grace periods, if any; or (v) the Issuer shall make a general assignment for the benefit of creditors; or (vi) the
Issuer shall file a petition for relief under any bankruptcy, insolvency or similar law (domestic or foreign); or (vii) an involuntary
proceeding shall be commenced or filed against the Issuer; or (viii} the Issuer shall lose its status as "OTC Eligible"
or the Issuer's shareholders shall lose the ability to deposit (either electronically or by physical certificates, or otherwise)
shares into the DTC System; or (ix) the Issuer shall become delinquent in its filing requirements as a fully-reporting issuer registered
with the SEC; or (x) the Issuer shall fail to meet all requirements to satisfy the availability of Rule 144 to the Investor or
its assigns including but not limited to timely fulfillment of its filing requirements as a fully-reporting issuer registered with
the SEC, requirements for XBRL filings, and requirements for disclosure of financial statements on its website.

 

8.                  
Remedies. In the event of any default, the outstanding principal amount of this Note,
plus accrued but unpaid interest, liquidated damages, fees and other amounts owing in respect thereof through the date of acceleration,
shall become, at the Investor's election, immediately due and payable in cash at the Mandatory Default Amount. The Mandatory Default
Amount means the greater of (i) the outstanding principal amount of this Note, plus all accrued and unpaid interest, liquidated
damages, fees and other amounts hereon, divided by the Conversion Price on the date the Mandatory Default Amount is either demanded
or paid in full, whichever has a lower Conversion Price, multiplied by the VWAP on the date the Mandatory Default Amount is either
demanded or paid in full, whichever has a higher VWAP, or (ii) 150% of the outstanding principal amount of this Note, pl us I 00%
of accrued and unpaid interest, liquidated damages, fees and other amounts hereon. Commencing five (5) days after the occurrence
of any event of default that results in the eventual acceleration of this Note, the interest rate on this Note shall accrue at
an interest rate equal to the lesser of 18% per annum or the maximum rate permitted under applicable law. In connection with such
acceleration described herein, the Investor need not provide, and the Issuer hereby waives, any presentment, demand, protest or
other notice of any kind, and the Investor may immediately and without expiration of any grace period enforce any and all of its
rights and remedies hereunder and all other remedies available to it under applicable law. Such acceleration may be rescinded and
annulled by the Investor at any time prior to payment hereunder and the Investor shall have all rights as a holder of the note
until such time, if any, as the Investor receives full payment pursuant to this Section.No such rescission or annulment shall affect
any subsequent event of default or impair any right consequent thereon. Nothing herein shall limit the Investor's right to pursue
any other remedies available to it at law or in equity including, without limitation, a decree of specific performance and/or injunctive
relief with respect to the Issuer's failure to timely deliver certificates representing shares of Common Stock upon conversion
of the Note as required pursuant to the terms hereof.

    	 

    	 

    

 

9.                  
No Shorting. The Investor agrees that so long as this Note from the Issuer to the Investor
remains outstanding, the Investor will not enter into or effect "short sales" of the Common Stock or hedging transaction
which establishes a net short position with respect to the Common Stock of the Issuer. The Issuer acknowledges and agrees that
upon delivery of a conversion notice by the Investor, the Investor immediately owns the shares of Common Stock described in the
conversion notice and any sale of those shares issuable under such conversion notice would not be considered short sales.

 

10.               
Assignability. The Issuer may not assign this Note. This Note will be binding upon
the Issuer and its successors and will inure to the benefit of the Investor and its successors and assigns and may be assigned
by the Investor to anyone without the Issuer's approval.

 

11.               
Governing Law. This Note will be governed by, and construed and enforced in accordance
with, the laws of the State of Nevada, without regard to the conflict of laws principles thereof. Any action brought by either
party against the other concerning the transactions contemplated by this Agreement shall be brought only in the state courts of
Florida or in the federal courts located i n Miami -Dade County, in the State of Florida. Both parties and the individuals signing
this Agreement agree to submit to the jurisdiction of such courts.

 

12.               
Delivery of Process by the Investor to the Issuer. In the event of any action or proceeding
by the Investor against the Issuer, and only by the Investor against the Issuer, service of copies of summons and/or complaint
and/or any other process which may be served in any such action or proceeding may be made by the Investor via U.S. Mail, overnight
delivery service such as FedEx or UPS, email, fax, or process server, or by mailing or otherwise delivering a copy of such process
to the Issuer at its last known attorney as set forth in its most recent SEC filing.

 

13.               
Attorney Fees. If any attorney is employed by either party with regard to any legal
or equitable action, arbitration or other proceeding brought by such party for enforcement of this Note or because of an alleged
dispute, breach, default or misrepresentation in connection with any of the provisions of this Note, the prevailing party will
be entitled to recover from the other party reasonable attorneys' fees and other costs and expenses incurred, in addition to any
other relief to which the prevailing party may be entitled.

 

14.               
Opinion of Counsel. In the event that an opinion of counsel is needed for any matter
related to this Note, the Investor has the right to have any such opinion provided by its counsel. Investor also has the right
to have any such opinion provided by Issuer's counsel.

 

15.               
Notices. Any notice required or permitted hereunder (including Conversion Notices)
must be in writing and either personally served, sent by facsimile or email transmission, or sent by overnight courier. Notices
will be deemed effectively delivered at the time of transmission if by facsimile or email, and if by overnight courier the business
day after such notice is deposited with the courier service for delivery.

    	 

    	 

    

 

	
        Issuer:

         

         

        /s/ Ben Chang

        Rich Pharmaceuticals, Inc.

        Chief Executive Officer

        Date: 8/10/14
	
        Investor:

         

         

        /s/ Authorized Signatory

        JMJ Financial

        Its Principal

        Date: 8/13/14

 

 

 

[Signature Page to $350,000 Convertible Note]

    	1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}]]